Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2016New England Journal of MedicineOpen Access

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

Christoph Wanner
Christoph WannerUniversity of Bergamo
Silvio E. Inzucchi
Silvio E. InzucchiUniversity of Vermont
John M. Lachin
John M. LachinMilken Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wanner et al. (2016) studied this question.

synapsesocial.com/papers/69dfc52960d9fa30ca7a0df9https://doi.org/10.1056/nejmoa1515920
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes2014 · 632 citations
  2. 2Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy2001 · 365 citations
  3. 3Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial2015 · 261 citations
  4. 4Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes2014 · 368 citations
  5. 5Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial2013 · 388 citations